Crohn’s
China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease
March 24, 2020Manufacturing and Production Crohn's, Takeda, Takeda China
China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis …
Top Ten most popular articles on Pharmafile.com this week
November 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten
While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
Takeda presents long-term Entyvio data in CD and UC
March 21, 2016Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis
Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
NICE u-turns on Entyvio for Crohn’s disease
July 10, 2015Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding
NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …
AbbVie and Galapagos extend deal
May 21, 2013Sales and Marketing AbbVie, Crohn's, Galapagos
AbbVie and Belgian biotech Galapagos have bolted on a development programme for Crohn’s disease to the selective JAK1 inhibitor they …
Another indication for Humira
November 28, 2012Sales and Marketing Abbott, Crohn's, EU, Humira
Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …
Signs of product payoff from GSK’s $1.5bn alliance
January 12, 2010Research and Development ChemoCentryx, Crohn's, GlaxoSmithKline
GlaxoSmithKline is to develop and commercialise a drug which hopes will be a treatment for moderate-to-severe Crohn’s disease. Californian biotech …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
